Key Points {#FPar1}
==========

Remaining adherent and persistent to antidepressant (AD) therapy is important to achieve therapeutic effect and potentially improve outcomes for patients with major depressive disorder (MDD).Using data from a large US insurance claims database, we found low adherence and persistence to AD therapy among patients with MDD over the year assessed.Results suggest that adherence and persistence may differ by therapeutic class.

Introduction {#Sec1}
============

Major depressive disorder (MDD) places a large burden on public health. Recent survey data suggest an increasing trend in the prevalence of depression, both in the USA and worldwide \[[@CR1], [@CR2]\]. It is estimated that 6.7% of the US population aged ≥18 years had a major depressive episode during 2013 \[[@CR3]\]. In 2000, the cost of depression in the US was estimated to be \$83.1 billion of lost lifetime earnings, accounting for both direct costs of care and indirect costs due to absenteeism, presenteeism, and suicide \[[@CR4]\].

The American Psychiatric Association (APA) supports pharmacological treatment of an episode of mild or moderate MDD with an antidepressant (AD) medication \[[@CR5]\]. Initiation (acute)-phase treatment encompasses the first 6--12 weeks of therapy, and continuation-phase treatment is recommended for at least an additional 4--9 months. Depending on response and the severity of the presenting episode, healthcare providers may attempt to further extend therapy (maintenance phase), switch AD therapy, or combine current therapy with a second AD or an adjunctive agent such as an antipsychotic medication. Compliance with AD treatment guidelines is associated with decreased probability of relapse \[[@CR6]--[@CR8]\] (defined as the reoccurrence of symptoms associated with the presenting MDD episode) and increased time to relapse \[[@CR9]\], highlighting the importance of adherence to pharmacological treatment.

Adherence, generally defined as following provider directions in regards to taking medication, is an important component of treatment \[[@CR5]\]. Persistence is defined as the duration of time until discontinuation of medication \[[@CR10]\]. AD medication adherence, as calculated through use of prescription claims data, is associated with positive health outcomes, such as decreased medical costs \[[@CR11], [@CR12]\] and potentially lower risk of mortality \[[@CR13]\]. Adherence and persistence across AD therapy has been estimated using insurance claims data or medical chart review, yet these estimates vary across the literature and are generally limited by exclusion of at least some clinically relevant time periods (i.e., clinically relevant time periods including 3 months' acute phase, 6 months' continuation phase, and both 9 and 12 months to reflect the maximum duration of acute and continuation phases).

In 2008, Sheehan et al. \[[@CR14]\] estimated that only 12--34% of patients with MDD remained adherent to initial AD therapy through 6 months, and, in 2010, Prukkanone et al. \[[@CR15]\] estimated that 23% of patients were adherent through 6 months. In contrast, Wu et al. \[[@CR16]\] estimated that 50% of patients were adherent to initial AD therapy through 6 months and Sawada et al. \[[@CR17]\] estimated that 56% were adherent and 44.3% were persistent to initial AD therapy through 6 months \[[@CR17]\]. The National Center for Quality Assurance (NCQA) State of Health Care 2014 report estimated that 47--49% of patients remained on AD therapy through 6 months \[[@CR18]\]. Taken together, these estimates represent both a large range and varied methods in calculating adherence and persistence; analyses were conducted in the USA, Japan, and Thailand using either insurance claims data or through chart review. It is also not clear whether differences in adherence or persistence across therapeutic classes exist, as few analyses have included all ADs; others have not directly compared across therapeutic classes.

Since publication of the article by Sheehan et al. \[[@CR14]\] in 2008, rates of adherence and persistence to more recently introduced ADs (vortioxetine, levomilnacipran, vilazodone, trazodone extended release, desvenlafaxine, and selegiline transdermal patches) have not been estimated. A comprehensive analysis of adherence and persistence to AD therapy is particularly warranted in real-world settings, focusing on any differences in adherence by initial therapeutic class. Thus, the objectives of this study were to describe the MDD population through a large US insurance claims database and to calculate adherence and persistence to initial AD therapy during clinically relevant time periods and by therapeutic class, including new ADs and formulations.

Methods {#Sec2}
=======

Data Source {#Sec3}
-----------

Truven Health Analytics MarketScan^®^ Research Databases were used for this study to assess US individuals from commercial, Medicare supplemental, and Medicaid insurance plans. These databases contain inpatient and outpatient medical claims linked to prescription medication claims representing US patients from all three of these types of insurance plans. The Medicaid database lacked patient-specific region data. This research did not meet the definition of Human Subjects Research because the dataset is de-identified at its source and is compliant with the Health Insurance Portability and Accountability Act of 1996 \[[@CR19], [@CR20]\].

Sample Selection {#Sec4}
----------------

### Inclusion Criteria {#Sec5}

Commercial, Medicare supplemental, and Medicaid databases were queried to identify claims between 1 July 2003 and 1 January 2014 (Fig. [1](#Fig1){ref-type="fig"}). Qualifying diagnoses for MDD included either one inpatient claim or one outpatient service claim with a second confirmatory claim (either inpatient or outpatient) within 60 days after the initial outpatient claim. MDD claims were identified using the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) codes for MDD single episode (296.2), MDD recurrent episode (296.3), dysthymic disorder (300.4), and depressive disorder not otherwise specified (311) \[[@CR14], [@CR21]\]. The first qualifying MDD claim to occur was defined as the index diagnosis date (IDD). Patients were required to have had continuous pharmacy and medical benefit eligibility from 6 months before to 12 months after the IDD. The index prescription date (IPD) was defined as the first pharmacy claim for an AD medication filled within 60 days before or after a qualifying diagnosis of MDD, which is similar to a prior claims analysis \[[@CR14]\]. Continuous insurance eligibility was re-assessed from 6 months before the IPD if the IPD preceded the IDD and 12 months after the IPD if the IPD followed the IDD. Pharmacy claims included all ADs used for the treatment of MDD (Appendix 1).Fig. 1Patient selection flowchart. ^a^One inpatient or one outpatient diagnosis with a confirmatory outpatient or inpatient diagnosis within 60 days. ^b^This 6-month period did not include the 60-day period immediately preceding the IDD. ^c^If the IPD was before the IDD, continuous enrollment eligibility was re-evaluated for 6 months prior to the IPD. If the IPD was after the IDD, eligibility was re-evaluated for 12 months post IPD, as defined in the exclusion criteria. ^d^As defined in exclusion criteria. *AA* adjunctive agent, *AD* antidepressant, *IDD* index diagnosis date, *IPD* index prescription date, *MDD* major depressive disorder

### Exclusion Criteria {#Sec6}

Patients were excluded if they had a diagnosis for MDD or an AD prescription claim in the 6 months before the IDD, excluding the 60-day period that preceded the IDD to account for the IPD definition. Patients who did not have continuous insurance coverage from 6 months before to 12 months after the IPD were excluded from the study. To ensure ADs were being used to treat a new diagnosis of MDD, patients with claims for certain conditions were excluded from the dataset if they occurred within 6 months before to 12 months after the IDD (Appendix 2). These include schizophrenic disorder (ICD-9 code: 295), bipolar disorder (296.0--296.1 and 296.4--296.9), other psychosis-related disorders, paranoid states (297), other mood disorders (293.83 and 301.13), drug-induced depression (292.84), depressive-type psychosis (298), Alzheimer's disease (331), Parkinson's disease (332), and dementia (290) \[[@CR12], [@CR14], [@CR22]\]. In addition, patients who had a claim for pregnancy (630--679) were excluded from the dataset because of the effect pregnancy may have on discontinuation of therapy. Patients were excluded if they initiated with two medications or had more than three medications prescribed within the first 60 days after the IPD. Initiating with two medications was defined as having two prescriptions for AD therapy on the IPD (or one AD and one adjunctive agent) or prescriptions for two ADs (or one AD and one adjunctive agent) that overlapped for more than 30 days within the first 60 days of the IPD (Appendix 1; therapeutic classifications were based on US Pharmacopeial Convention Medicare Model Guidelines v6.0 \[[@CR23]\]). Overlapped days were not required to be consecutive. If patients did not meet the definition of initiating with two medications or more than three medications as defined, no further exclusion criteria were applied.

Calculation of Adherence and Persistence {#Sec7}
----------------------------------------

Adherence was calculated considering adherence to the initial AD medication, to the initial AD therapeutic class, and to AD therapy overall (Fig. [2](#Fig2){ref-type="fig"}). Monotherapy was assumed for calculations of adherence. Each calculation was assessed at 3, 6, 9, and 12 months after the IPD. The 3-month time frame was chosen based on the Antidepressant Medication Management (AMM) quality measure for effective initiation treatment \[[@CR24]\]. The 6-month time frame was chosen based on the minimum duration of therapy to achieve both initiation and continuation treatment, its use in the AMM quality measure for effective continuation treatment \[[@CR5]\], and use in prior adherence and persistence analyses \[[@CR14]--[@CR17], [@CR25], [@CR26]\]. Adherence was also calculated at 9 and 12 months, as the added duration of initiation and continuation phase allows up to a full year of therapy \[[@CR5], [@CR27]\]. Calculations of adherence such as medication possession ratio (MPR) and proportion of days covered (PDC) are well-defined \[[@CR10], [@CR12], [@CR28], [@CR29]\]. PDC was chosen as the primary calculation of adherence because it accounts for overlap of prescriptions and is considered a preferred measure of adherence \[[@CR30]\]. MPR was also calculated to ensure similar results between calculations. MPR values over 1.0 were truncated to 1.0. Both PDC and MPR were calculated over each time frame as the total number of days that the medication was available or the days' supply, respectively, and divided by the period of follow-up. Adherence was dichotomized as adherent if PDC (or MPR) was ≥0.80 and not adherent if PDC (or MPR) was \<0.80, as this threshold is commonly used and supported to have predictive ability to estimate risk of hospitalization \[[@CR31]\].Fig. 2Index prescription date identification (**a**) and identification of relevant prescription claims to calculate adherence and persistence (**b**). ^a^IPD was the first claim for an AD prescription that occurred within 60 days before or after a qualifying MDD diagnosis date. ^b^Continuous enrollment assessed principally from the IDD and was then re-assessed from the IPD. **b** Consider a patient who receives citalopram (first and second prescription; *yellow*), escitalopram (third prescription; *red*), and then desvenlafaxine (fourth prescription; *blue*). Prescription claims relevant to calculations are identified by calculation type: (1) to initial AD medication (*yellow* prescription claims only), (2) to initial therapeutic class (*yellow* and *red* prescription claims only), and (3) to AD therapy overall (*yellow*, *red*, and *blue* prescription claims). *AD* antidepressant, *IDD* index diagnosis date, *IPD* index prescription date, *MDD* major depressive disorder

Persistence was also calculated considering persistence to the initial AD medication, to the initial therapeutic class, and to AD therapy overall. Each calculation was also assessed at 3, 6, 9, and 12 months after the IPD. Persistence was defined as the days of treatment until a 30-day gap in therapy, and the gap was chosen based on the AMM quality measure for effective acute-phase treatment \[[@CR24]\] and use in prior claims analyses \[[@CR32], [@CR33]\]. Persistence was calculated until patients discontinued therapy, were lost to follow-up due to loss of insurance eligibility after a minimum of 12 months' continuous enrollment, or were followed for a maximum of 2 years (730 days), whichever occurred first. Persistence in days was similarly converted to a dichotomous outcome as persistent or not persistent to each time frame.

Demographic and Clinical Variables {#Sec8}
----------------------------------

Baseline demographic covariates included age, sex, source of insurance claim, region in which medical care was received, and type of health plan. Clinical covariates included MDD diagnosis code (single episode, recurrent episode, dysthymic disorder, depression not otherwise specified) and Charlson Comorbidity Index (CCI) score (0, 1, 2, 3, or greater). The CCI was calculated as an indicator of mortality risk over the year prior to the IDD using the Deyo modification \[[@CR34]\].

Subgroups of Interest {#Sec9}
---------------------

Patients with a diagnosis of anxiety and chronic non-cancer pain disorders were of interest because certain AD therapy is US FDA labeled or used off-label to treat these comorbidities. Diagnosis of cancer pain was not of interest because guidelines support analgesic therapy for management of pain \[[@CR35]\]. Patients were identified through ICD-9 codes \[[@CR14], [@CR26], [@CR36], [@CR37]\] (Appendix 2) within 60 days before or after the IDD. For the chronic non-cancer pain disorder of chronic low back pain, claims were identified up to 6 months before the IDD or 60 days after, to account for treatment progression over time.

Statistical Analyses {#Sec10}
--------------------

Descriptive statistics were used to characterize baseline demographics, clinical characteristics, and subgroups. Means and standard deviations (SDs) were used to describe continuous variables, and counts and proportions were used for categorical variables. Bivariate statistics for differences in characteristics across therapeutic classes were conducted using Chi squared (*χ* ^2^) tests for categorical variables and analysis of variance (ANOVA) for continuous variables. Adherence outcomes and persistence outcomes were interpreted based on descriptive results and compared using inferential statistics. Specifically, we compared the proportion adherent or persistent from the IPD to 3-month time frame separately to each other timeframe (IPD to 6, 9, and 12-months time frames) using McNemar's *χ* ^2^ tests. Persistence on therapy (time to discontinuation) between therapeutic classes was compared using the Kaplan--Meier estimator and log-rank test.

Unadjusted logistic regressions were conducted on the complete cohort to estimate the odds of adherence to initial therapeutic class versus selective serotonin reuptake inhibitor (SSRI) therapy for each time frame (from IPD to 3, 6, 9, or 12 months). The SSRI referent group was chosen based on a majority of the cohort having been initially prescribed SSRI therapy. Multivariable logistic regression was conducted to provide adjusted estimates for each time frame, and the model included all baseline demographic and clinical characteristics as well as the presence of a comorbid anxiety or chronic non-cancer pain disorder. Covariates for the adjusted model were chosen based on statistical, clinical, and epidemiological rationale. All analyses were performed using the statistical software package STATA^®^ version 13 \[[@CR38]\]. A significance level of *α* = 0.05 was chosen for all analyses.

Sensitivity Analyses {#Sec11}
--------------------

A sensitivity analysis was performed for persistence using a 45-day gap in therapy as a cut-off and was compared with the primary analysis that used a 30-day gap in therapy as a cut-off.

Results {#Sec12}
=======

Population {#Sec13}
----------

Of the estimated 200 million patients in Marketscan^®^ Databases, we identified 6,562,955 patients with qualifying diagnoses of MDD from 1 July 2003 to 1 January 2014 (Fig. [1](#Fig1){ref-type="fig"}). After inclusion and exclusion criteria were applied, 574,753 patients received a new prescription for AD therapy. Of the 574,753 patients, another 36,651 were excluded because they initiated with two ADs and augmentative agents and another 10,195 because they initiated with three or more ADs and augmentative agents. Finally, 527,907 patients were included in the analysis of adherence and persistence. The left-skewed distribution of initial prescriptions indicated higher prescription density during the later years of the selection period, yet this increase in density was similar across therapeutic classes (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Distribution of index prescriptions by year and initial therapeutic class. *AD* antidepressant, *MAOI* monoamine oxidase inhibitor, *SNRI* serotonin and norepinephrine reuptake inhibitor, *SSRI* selective serotonin reuptake inhibitor, *TCA* tricyclic antidepressant

The average (SD) age of the study population was 38 (17) years. The majority of subjects were female (64%) and covered by commercial insurance plans (81%); preferred provider organizations and health maintenance organizations (48 and 20%) were the most common insurance plan types (Table [1](#Tab1){ref-type="table"}; Appendix 3). The largest proportion of the sample resided in the southern region of the USA (29%). Of the four MDD-specific diagnostic codes, the most common index diagnosis was depression not otherwise specified (56%). The analytic cohort had low mortality risk, as demonstrated by the majority (79%) having a CCI score of 0, yet 24% had comorbid anxiety disorders, 24% had comorbid chronic non-cancer pain disorders, and 6% had both. The proportion of patients with comorbid anxiety disorders was similar across therapeutic classes, whereas a greater proportion of patients with comorbid chronic non-cancer pain disorders were initially prescribed serotonin and norepinephrine reuptake inhibitors (SNRIs) and tricyclic ADs (TCAs) in comparison with other therapeutic classes (31 and 52%, respectively). The most commonly prescribed AD therapeutic class was SSRI (73.5% of cohort). The most common SSRI prescribed was sertraline (18.7% of cohort), and the most common AD prescribed from the other AD therapeutic classes was bupropion extended release (5.4%). No patients received an initial isocarboxazid prescription, probably because it is used as a second-line therapy, or initial prescriptions for vortioxetine or levomilnacipran, most likely because they were only recently approved by the FDA to treat MDD \[[@CR39], [@CR40]\].Table 1Demographic and clinical characteristics of the cohort and presence of anxiety or chronic pain disordersCharacteristicsAll antidepressant classes (*N* = 527,907)Demographic variables Antidepressant class \[no. of prescriptions (%)\]  SSRI387,746 (73)  Other AD71,664 (14)  SNRI57,342 (11)  TCA11,070 (2)  MAOI85 (\<1) Mean age (SD), years38 (17) Age categories, years  \<1883,293 (16)  18--39192,724 (37)  40--65222,532 (42)  \>6529,358 (6) Sex  Female338,226 (64)  Male189,681 (36) Insurance claim source  Commercial425,106 (81)  Medicaid71,710 (14)  Medicare31,091 (6) Geographical location  South150,913 (29)  Northcentral127,340 (24)  West99,265 (19)  Northeast72,143 (14)  Missing71,710 (14)  Unknown6536 (1) Health plan type  PPO255,337 (48)  HMO103,521 (20)  Comprehensive75,235 (14)  POS38,915 (7)  CDHP16,164 (3)  Missing15,282 (3)  POS with capitation10,772 (2)  HDHP8208 (2)  EPO4473 (\<1)Clinical variables MDD diagnosis code  Depression, NOS293,311 (56)  Recurrent episode95,652 (18)  Single episode71,942 (14)  Dysthymia67,002 (13) CCI (Deyo Modification) in the 12 months pre-IDD  0419,089 (79)  170,158 (13)  219,370 (4)  3+19,290 (4)Subgroups of interest Comorbid diagnoses^a^  Anxiety disorder125,319 (24)  Chronic non-cancer pain disorder124,170 (24)Data are presented as *n* (%) unless otherwise indicatedThe CCI was calculated using the Deyo modification in the year prior to the index MDD diagnosis date*AD* antidepressant, *CCI* Charlson Comorbidity Index, *CDHP* consumer-driven health plan, *EPO* exclusive provider organization, *HDHP* high deductible health plan, *HMO* health maintenance organization, *IDD* index diagnosis date, *MAOI* monoamine oxidase inhibitor, *MDD* major depressive disorder, *NOS* not otherwise specified, *POS* point of service, *PPO* preferred provider organization, *SD* standard deviation, *SNRI* serotonin and norepinephrine reuptake inhibitor, *SSRI* selective serotonin reuptake inhibitor, *TCA* tricyclic antidepressant^a^Comorbid anxiety disorders and chronic non-cancer pain disorder were identified within 60 days before or after the IDD, with the exception of the chronic non-cancer pain disorder: low back pain (Appendix 2). For this disorder only, chronic low back pain was identified up to 6 months before the IDD to 60 days after to capture the progression of treatment over time

Adherence and Persistence {#Sec14}
-------------------------

Both adherence and persistence decreased significantly over the year of therapy for each of the three calculations: to initial AD medication, initial therapeutic class, and AD therapy overall. Yet, adherence and persistence were slightly higher to initial therapeutic class and to AD therapy overall when compared with initial AD medication. Adherence at 6 months by the three calculations was 31, 33, and 35% (Fig. [4](#Fig4){ref-type="fig"}a), where persistence at 6 months was 31, 33, and 36% (Fig. [4](#Fig4){ref-type="fig"}b). When adherence and persistence to initial AD medication were stratified by therapeutic class, both similarly decreased over the year of therapy (Fig. [5](#Fig5){ref-type="fig"}a, b). Patients initially prescribed SNRIs had the highest adherence and persistence at all time frames (at 6 months, 37 and 37%, respectively) compared with the other therapeutic classes, whereas TCAs had the lowest adherence and persistence (at 6 months, 16 and 17%, respectively). Adherence was slightly higher when calculated using MPR, yet the results were similar.Fig. 4Adherence (**a**) and persistence (**b**) by calculation type over the first 3, 6, 9, and 12 months after index prescription date. *AD* antidepressant. \**p* \< 0.0001 vs. adherence to 3 months (McNemar's paired *χ* ^*2*^ test of equality of proportions) Fig. 5Proportion adherent (**a**) and persistent (**b**) to initial antidepressant medication at the first 3, 6, 9, and 12 months after index prescription date, by therapeutic class. *AD* antidepressant, *MAOI* monoamine oxidase inhibitor, *SNRI* serotonin and norepinephrine reuptake inhibitor, *SSRI* selective serotonin reuptake inhibitor, *TCA* tricyclic antidepressant. \**p* \< 0.01, \*\**p* \< 0.0001 vs. adherence to 3 months (McNemar's paired χ^2^ test of equality of proportions)

Upon sensitivity analysis, persistence was slightly higher using the 45-day persistence cut-off versus the 30-day cut-off, yet the results were similar across therapeutic classes over the year of therapy. Persistence at 6 months using a 45-day gap was 37% for SSRIs, 30% for other ADs, 42% for SNRIs, 20% for TCAs, and 41% for monoamine oxidase inhibitors (MAOIs).

A Kaplan--Meier time-to-discontinuation curve of initial AD medication, by therapeutic class, described the persistence outcome continuously (Fig. [6](#Fig6){ref-type="fig"}). The commonality among insurance plans of covering a 30-day supply of medication at a time likely accounted for the pattern of drop-off at 30, 60, and 90 days. The curves differed by therapeutic class (*p*-value \<0.0001), with lower persistence to initial TCA therapy at all time points, and at 270 days, with lower persistence to initial MAOI therapy.Fig. 6Time to discontinuation of initial antidepressant medication by therapeutic class. *AD* antidepressant, *MAOI* monoamine oxidase inhibitor, *SNRI* serotonin and norepinephrine reuptake inhibitor, *SSRI* selective serotonin reuptake inhibitor, *TCA* tricyclic antidepressant. *p* \< 0.0001 comparing therapeutic classes (log-rank test)

Our logistic regression results found differences in the odds or likelihood of adherence to initial AD medication across therapeutic classes. The adjusted odds of adherence at 6 months were 23% higher for patients initiating with SNRI therapy versus SSRI therapy \[Fig. [7](#Fig7){ref-type="fig"}; odds ratio (OR) 1.23; 95% confidence interval (CI) 1.21--1.25; *p*-value \<0.0001\]. For patients initiating with the other AD or TCA therapeutic classes, the adjusted odds of adherence at 6 months were 23% (OR 0.77; 95% CI 0.75--0.78) and 55% (OR 0.45; 95% CI 0.42--0.47) lower, respectively (*p*-values \<0.0001; Fig. [7](#Fig7){ref-type="fig"}). Adherence among patients initiating with MAOIs was not significantly different compared with those initiating with SSRIs. Similar results were found to the 3-, 9-, and 12-months time frames (Appendix 4).Fig. 7Adjusted odds of adherence at 6 months versus initial selective serotonin reuptake inhibitor therapy^a,b^. \**p* \< 0.0001 vs. initial selective serotonin reuptake inhibitor therapy. ^a^Results (odds ratios of adherence and 95% confidence intervals) were similar for the 3-, 9-, and 12-month time frames. Results for monoamine oxidase inhibitors were non-significant at all timeframes and were not shown here because of small sample size (*n* = 85, odds ratio = 1.00, 95% confidence interval 0.64--1.56). ^b^Covariates included baseline demographic covariates: age, sex, source of insurance claim, region in which medical care was received, and type of health plan. Clinical covariates were major depressive disorder diagnosis code, Charlson Comorbidity Index, presence of a comorbid anxiety disorder, and presence of a comorbid chronic non-cancer pain disorder. *AD* antidepressant, *SNRI* serotonin and norepinephrine reuptake inhibitor, *TCA* tricyclic antidepressant

Discussion {#Sec15}
==========

The purpose of this analysis was to assess and compare adherence and persistence to initial AD medication across therapeutic classes for the MDD population. It is the largest retrospective study using insurance claims data to date for an MDD-specific population, in both sample size and number of ADs included. The results support that adherence and persistence is low across therapeutic classes in a "real-world" setting. Similar to previously reported estimates, this analysis found that the proportion adherent at 6 months was higher with SNRI or SSRI therapy than with TCAs \[[@CR14], [@CR41]\]. Yet, the proportion adherent at 6 months to MAOIs was similar to SSRI or SNRI therapy, which was unexpected and likely due to the small sample size (*n* = 85). The proportion persistent was also consistent with the literature \[[@CR17], [@CR26], [@CR42]\].

Adherence and persistence calculations were compared to the initial AD medication, to initial therapeutic class, and to AD therapy overall. Adherence to initial class and overall to AD therapy was slightly higher than adherence to initial AD medication, indicating that a small subset of patients who discontinue their initial AD medication switch to another AD from the same or a different therapeutic class. However, for the majority of patients, AD therapy was discontinued much earlier than the clinically recommended 6- to 9-months period, and this discontinuation primarily occurred over the first 3 months of therapy. Results suggest that switching between ADs did not fully account for low adherence and persistence over the year of therapy assessed. Our findings support that adherence and persistence to AD therapy is similar to or lower than that for the suboptimal medication adherence and persistence reported for other chronic disease states, including hypertension, gout, overactive bladder syndrome, glaucoma (to prostaglandin eye-drop therapy), and diabetes (to oral glycemic control medications) \[[@CR43], [@CR44]\]. This demonstrates suboptimal adherence and persistence to AD therapy in the MDD population.

The likelihood of remaining adherent over the year of therapy differed by the initial therapeutic class prescribed, highlighting the potential importance of initial choice of AD therapy. Those initially prescribed SNRI therapy had increased odds of adherence versus those receiving SSRI therapy over the year of therapy, whereas those initially prescribed ADs from the other AD classes and TCA class had lower odds of adherence than those receiving SSRIs. The odds of adherence for patients initially prescribed MAOIs were no different from those receiving SSRI therapy. Interestingly, the odds of adherence differed by MDD diagnosis code. Specifically, patients with an index diagnosis of dysthymic disorder had increased odds of adherence to initial therapy compared with patients diagnosed with a single episode of MDD, after adjusting for all other covariates (Appendix 4).

Adherence may be related to a perceived or experienced clinical benefit to the patient. A review conducted in 2005 suggested a potential difference in the rate of response to therapy and remission with venlafaxine versus other antidepressants \[[@CR45]\]. Although evidence suggests adverse events may be similar when comparing SNRIs and SSRIs, SNRIs may pose an advantage to treating depression-associated neuropathic pain and other pain.

Limitations {#Sec16}
===========

Use of insurance claims data may pose a risk of misclassification bias because of entry errors and consolidation of information across health plans, or incomplete information, as insurance claims that are not linked with an individual's primary insurance may not be captured. Importantly, clinical and demographic information in claims lack validation to medical record data. The prevalence of AD prescription in the sample also may not reflect prescribing practices, as patients may not fill AD prescriptions that they receive from healthcare providers. Yet, as our sample was large and diverse, prescribing patterns likely echoed current practice. Assessing adherence and persistence through analyses of claims data may not reflect true adherence and persistence, as our calculations assume patients take the prescriptions they fill. Alternative clinical instructions or use may also lead to underestimation of adherence. For example, the SSRI trazodone is commonly used off-label at low doses for its sedative properties and is not typically used to treat MDD \[[@CR5]\], and new clinical guidance for elderly patients with MDD may contribute to discontinuation of therapy per provider instruction.

While observational studies such as ours are necessary for evaluating "real-world" conditions, they have a higher potential for bias than randomized controlled trials. Use of claims data did not allow for control of all possible factors that may be associated with adherence, including clinical factors related to patient care. To the extent possible, we addressed this by including many potential confounders and precision variables in the adjusted analyses: age, sex, source of insurance, geographical region, insurance plan type, MDD diagnosis code, CCI, and presence of anxiety or chronic non-cancer pain comorbidities. Multivariable logistic regression was used to adjust for these variables; although a method applying propensity score matching was considered, results were expected to be similar because the same covariates would be included to create the propensity score. Certain clinical and psychosocial factors that may be associated with adherence, such as the provider's title (e.g. family practitioner vs. psychiatrist), provider practice models, past treatment for MDD, clinical response and occurrence of adverse drug events, patient beliefs, patient--provider relationship, patient education, and patient economic and cultural factors, were not available in the insurance claims database \[[@CR5]\].

Our study strengthens the need for future research in another database or with prospectively collected data that characterizes clinical and psychosocial factors that may influence patient adherence and persistence, particularly the role of the provider.

Conclusion {#Sec17}
==========

Based on a retrospective analysis of a large insurance claims database, we found that patients with MDD demonstrated low adherence and persistence to initial AD therapy. Adherence and persistence overall to AD therapy was only 35 and 36%, respectively, at 6 months after initiating therapy. Our results suggest that adherence may differ by therapeutic class; patients initiating SNRI therapy appeared to have a higher likelihood of adherence than those receiving initial SSRI therapy over the year assessed. Persistence may also differ by therapeutic class, with initial SNRI therapy appearing to be associated with greater persistence than other therapeutic classes over the year assessed. Taking into account limitations of the insurance claims database when interpreting these results, further study is required to confirm our findings and determine additional drivers, such as pharmacological properties and other clinical variables, of these apparent differences by AD therapeutic class.
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